Study of a new drug for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell non-Hodgkin lymphoma, which is a cancer of certain white blood cells.
- You must have tried standard treatments and they are not working, or there is no standard treatment that is a good option for you.
- You need to be able to care for yourself and do most daily activities (this is called a performance status of 0 or 1).
- Your cancer must be measurable, meaning it can be seen on scans or tests.
- If you are pregnant, breastfeeding, or planning to have a child, you will need to follow strict birth control rules during the study.
- You cannot have active lymphoma in your brain or the fluid around your brain.
- You must not have had an organ transplant or a different cancer (except some skin cancers or early cervical cancer) in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (GSK5926371) for people with a type of lymphoma (B-cell NHL) that has come back or not responded to earlier treatments. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.